Chimeron Bio
Chimeron Bio is a biotechnology company dedicated to advancing genetic medicine and transforming cancer treatment. They develop groundbreaking therapies leveraging innovative science to achieve unparalleled gene expression and therapeutic potency, focusing on in vivo CAR-T therapies, immuno-oncology, and cancer vaccines. Their proprietary ChaESAR™ platform enables delivery of multiple genes, large payloads, and targeted delivery, aiming to create impactful treatments for cancer, infectious diseases, and genetic disorders.
Industries
Nr. of Employees
small (1-50)
Chimeron Bio
Products
Self-amplifying mRNA COVID-19 vaccine candidate (CB-106)
A preclinical self-amplifying mRNA vaccine candidate delivering the viral Spike gene designed for low-dose immunogenicity and progression through non-clinical evaluation.
Multiplex nanoparticle-based vaccine and therapeutic platform
A delivery platform that packages multiple RNA payloads into a single particle to enable multi-pathway therapeutic interventions, cancer vaccines, and in vivo CAR approaches.
Self-amplifying mRNA COVID-19 vaccine candidate (CB-106)
A preclinical self-amplifying mRNA vaccine candidate delivering the viral Spike gene designed for low-dose immunogenicity and progression through non-clinical evaluation.
Multiplex nanoparticle-based vaccine and therapeutic platform
A delivery platform that packages multiple RNA payloads into a single particle to enable multi-pathway therapeutic interventions, cancer vaccines, and in vivo CAR approaches.
Services
Design and preclinical evaluation of saRNA-based vaccine and therapeutic candidates, including animal-model testing and translational studies.
Process transfer and scale-up of RNA drug-substance manufacturing to a cGMP contract development and manufacturing organization to produce bulk drug substance for IND-enabling work.
Engagements with life-science suppliers and grant programs to obtain in-kind products, technical support, and grant-funded resources to accelerate platform development.
Design and preclinical evaluation of saRNA-based vaccine and therapeutic candidates, including animal-model testing and translational studies.
Process transfer and scale-up of RNA drug-substance manufacturing to a cGMP contract development and manufacturing organization to produce bulk drug substance for IND-enabling work.
Engagements with life-science suppliers and grant programs to obtain in-kind products, technical support, and grant-funded resources to accelerate platform development.
Expertise Areas
- Self-amplifying RNA therapeutics and vaccines
- Nanoparticle-based RNA delivery
- In vivo CAR therapeutic development
- Cancer vaccines and immuno-oncology
Key Technologies
- Self-amplifying RNA (saRNA)
- Multiplexed nanoparticle delivery
- In vivo CAR delivery methods
- Ligand-directed targeted nanoparticle uptake
News & Updates
Chimeron Bio received a 2024 NIH Small Business Innovation Research Award to develop a cancer vaccine against inherited colorectal cancer using their self-amplifying mRNA platform and multiplexed nanoparticle.
Chimeron Bio was recognized as a finalist in the MilliporeSigma Advance Biotech Grant Award, supporting their efforts to develop next-generation RNA therapeutics.
Antonin de Fougerolles, former founding CSO of Moderna and a pioneer in RNA technology, was appointed to Chimeron Bio's Board of Directors.
Kevin Heyeck, with extensive experience in life sciences and venture capital, was appointed as CEO to support the company's growth and pipeline development.
Chimeron Bio received a 2024 NIH Small Business Innovation Research Award to develop a cancer vaccine against inherited colorectal cancer using their self-amplifying mRNA platform and multiplexed nanoparticle.
Chimeron Bio was recognized as a finalist in the MilliporeSigma Advance Biotech Grant Award, supporting their efforts to develop next-generation RNA therapeutics.
Antonin de Fougerolles, former founding CSO of Moderna and a pioneer in RNA technology, was appointed to Chimeron Bio's Board of Directors.
Kevin Heyeck, with extensive experience in life sciences and venture capital, was appointed as CEO to support the company's growth and pipeline development.